List of Dyloject drug patents
Dyloject is owned by Javelin Pharms Inc.
Dyloject contains Diclofenac Sodium.
Dyloject has a total of 1 drug patent out of which 0 drug patents have expired.
Dyloject was authorised for market use on 23 December, 2014.
Dyloject is available in solution;intravenous dosage forms.
Dyloject can be used as management of pain.
The generics of Dyloject are possible to be released after 22 March, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8946292 | JAVELIN PHARMS INC | Formulations of low dose diclofenac and beta-cyclodextrin |
Mar, 2027
(4 years from now) | |
Drugs and Companies using DICLOFENAC SODIUM ingredient
Market Authorisation Date: 23 December, 2014
Treatment: Management of pain
Dosage: SOLUTION;INTRAVENOUS
DYLOJECT family patents
6
United States
5
Korea, Republic of
3
Japan
3
European Union
2
Israel
2
China
1
Australia
1
Canada
1
Mexico
1
South Africa
1
Brazil
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic